

Economic Impact of a triptan Rx-To-OTC Switch in Six

PLoS ONE

8, e84088

DOI: [10.1371/journal.pone.0084088](https://doi.org/10.1371/journal.pone.0084088)

Citation Report

#	ARTICLE	IF	CITATIONS
1	From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006â€“2015: pharmacological perspectives on regulatory decisions. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 901-910.	0.8	8
2	Unsuccessful applications to increase or decrease the over-the-counter (OTC) availability of drugs in Germany between 2009 and 2014. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2017, 25, 321-331.	0.8	2
3	The value of self-medication: summary of existing evidence. <i>Journal of Medical Economics</i> , 2018, 21, 201-211.	1.0	70
4	Migraine burden and costs in France: a nationwide claims database analysis of triptan users. <i>Journal of Medical Economics</i> , 2019, 22, 616-624.	1.0	4
5	Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions. <i>Value in Health</i> , 2019, 22, 293-302.	0.1	4
6	Key results of a series of surveys among German pharmacies, physicians, patients and stakeholders regarding further triptans as potential OTC products. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2022, 30, 409-415.	0.8	0
7	Widening Consumer Access to Medicines through Switching Medicines to Non-Prescription: A Six Country Comparison. <i>PLoS ONE</i> , 2014, 9, e107726.	1.1	37
8	Potential Rx-to-OTC Switch Drug Candidates. <i>Innovations in Pharmacy</i> , 2016, 7, .	0.2	2
9	Managing migraine with over-the-counter provision of triptans: the perspectives and readiness of Western Australian community pharmacists. <i>PeerJ</i> , 2019, 7, e8134.	0.9	4
10	Application of an economic evaluation approach to making regulatory decisions regarding access to medicines: advantages, challenges and recommendations. <i>Australian Health Review</i> , 2021, , .	0.5	0
11	Does self-medication reduce medical expenditure among the middle-aged and elderly population? A four-wave longitudinal study in China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	6